[go: up one dir, main page]

UY31750A - Compuestos y composiciones como inhibidores de quinasa - Google Patents

Compuestos y composiciones como inhibidores de quinasa

Info

Publication number
UY31750A
UY31750A UY0001031750A UY31750A UY31750A UY 31750 A UY31750 A UY 31750A UY 0001031750 A UY0001031750 A UY 0001031750A UY 31750 A UY31750 A UY 31750A UY 31750 A UY31750 A UY 31750A
Authority
UY
Uruguay
Prior art keywords
compositions
compounds
quinasa
inhibitors
quinasa inhibitors
Prior art date
Application number
UY0001031750A
Other languages
English (en)
Inventor
Jiang Tao
Zhu Xuefeng
Pei Wei
Truc Ngoc Nguyen
Wu Baogen
Pierre Y Ves Michellys
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of UY31750A publication Critical patent/UY31750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se rediere a composiciones de triazina y pirimidina y mètodos para utilizar las composiciones de la Fórmula (1) o (2): donde R1, R2, R3, R4, R5, X Y, Z1, Ph, B m, n son como se los definió anteriormente.
UY0001031750A 2008-04-07 2009-04-03 Compuestos y composiciones como inhibidores de quinasa UY31750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US9588308P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
UY31750A true UY31750A (es) 2009-12-14

Family

ID=40786670

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031750A UY31750A (es) 2008-04-07 2009-04-03 Compuestos y composiciones como inhibidores de quinasa

Country Status (13)

Country Link
US (1) US8518931B2 (es)
EP (1) EP2271645A1 (es)
JP (1) JP5214799B2 (es)
KR (1) KR20110002080A (es)
CN (1) CN102056925A (es)
AR (1) AR071300A1 (es)
AU (1) AU2009233963B2 (es)
BR (1) BRPI0910979A2 (es)
CA (1) CA2720944C (es)
EA (1) EA018484B1 (es)
MX (1) MX2010011069A (es)
UY (1) UY31750A (es)
WO (1) WO2009126514A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2428508T3 (en) 2009-05-08 2016-02-01 Astellas Pharma Inc Diamino heterocyclic carboxamide COMPOUND
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2867233A1 (en) 2012-07-03 2015-05-06 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
JP6359020B6 (ja) 2012-11-06 2018-08-15 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Ａｌｋキナーゼ阻害剤
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
EA032255B1 (ru) * 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (es) 1973-05-22 1974-11-26
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
MXPA05008955A (es) * 2003-02-28 2006-02-22 Teijin Pharma Ltd Derivados de pirazolo [1,5-a] pirimidina.
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
JP2006160628A (ja) * 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
US7741318B2 (en) * 2004-12-21 2010-06-22 Schering Corporation Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
US8518931B2 (en) 2013-08-27
MX2010011069A (es) 2010-11-12
EA018484B1 (ru) 2013-08-30
AU2009233963A1 (en) 2009-10-15
JP5214799B2 (ja) 2013-06-19
AU2009233963B2 (en) 2011-10-06
CN102056925A (zh) 2011-05-11
JP2011516554A (ja) 2011-05-26
EA201001596A1 (ru) 2011-04-29
BRPI0910979A2 (pt) 2016-01-05
EP2271645A1 (en) 2011-01-12
WO2009126514A1 (en) 2009-10-15
CA2720944C (en) 2012-12-18
CA2720944A1 (en) 2009-10-15
US20110190264A1 (en) 2011-08-04
AR071300A1 (es) 2010-06-09
WO2009126514A8 (en) 2010-10-21
KR20110002080A (ko) 2011-01-06

Similar Documents

Publication Publication Date Title
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
MX2012002973A (es) Derivados de pirimidona herbicidas.
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
UY29612A1 (es) Compuestos quimicos ii
EA200900945A1 (ru) Новый способ синтеза агомелатина
EA201170282A1 (ru) Фунгицидные n-циколоалкил-n-бифенилметилкарбоксамидные производные
BRPI0511933A (pt) derivados de quinazolinona úteis como antagonistas de vanilóide
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
MX2022003023A (es) Compuestos heterociclicos.
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
UY30545A1 (es) Derivados sustituidos del acido acilamino-benzoico, composiciones que los contienen y aplicaciones
EA200900943A1 (ru) Новый способ синтеза агомелатина
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
ECSP12011678A (es) Metilpirrolopirimidincarboxamidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181025